Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of trabectedin [ET 743] for the treatment of Japanese patients with malignant soft tissue sarcoma of histological types (chromosomal translocations)

Next Previous
Trial Profile

Phase II trial of trabectedin [ET 743] for the treatment of Japanese patients with malignant soft tissue sarcoma of histological types (chromosomal translocations)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Taiho Pharmaceutical

Most Recent Events

  • 28 Sep 2015 According to a Taiho Pharmaceutical Co., media release, trabectedin (Yondelis) received marketing approval from the MHLW for the treatment of patients with soft tissue sarcoma in Japan.
  • 01 Sep 2015 According to a PharmaMar media release, the Japanese Pharmaceutical Affairs and Food Sanitation Council (PAFSC) has recommended approval of trabectedin for the treatment of patients with soft tissue sarcoma in Japan. The PAFSC provided a positive opinion to the Japanese Ministry of Health, Labour and Welfare (MHLW) based on the review report prepared by the Japanese regulatory agency (PMDA) for trabectedin. MHLW will issue the marketing authorization based on this recommendation.
  • 21 Jun 2014 New source identified and integrated Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top